Literature DB >> 28694923

Molecular genetic changes in benign colorectal tumors synchronous with microsatellite unstable carcinomas do not support a field defect.

Peter Zauber1, Stephen Marotta2, Marlene Sabbath-Solitare2.   

Abstract

BACKGROUND: A colorectal cancer may develop through a particular molecular genetic pathway, raising the question of whether the particular molecular changes are random, or are unique to the particular segment of colon. We wanted to determine whether molecular changes found within a colorectal cancer might also be detected in separate adenomas and polyps removed from the same area of colon at surgery. Microsatellite instability was chosen as a marker for a pathway of colon carcinogenesis.
METHODS: We studied a total of 46 primary colorectal cancers with microsatellite instability and 77 synchronous adenomas and polyps. All tumors were evaluated for microsatellite instability, BRAF and KRAS mutations, and methylation using standard polymerase chain reaction based methods.
RESULTS: Forty-nine benign tumors did not follow a pathway similar to that of their 31 synchronous primary cancers. For two distinct subsets of the microsatellite unstable colorectal cancers, those with acquired methylation and BRAF mutation, and those without methylation suggestive of an underlying germ line mutation, the molecular changes in the majority of their synchronous benign tumors were different from the colorectal cancer.
CONCLUSIONS: These differences suggest a stochastic process within the colon regarding the particular molecular carcinogenic pathways followed by the synchronous tumors, rather than a 'field defect' within the colon segments. Variability in molecular findings was present for colorectal cancers arising from acquired methylation, as well as those cancers suggestive of a germ line origin.

Entities:  

Keywords:  Adenoma; BRAF gene; KRAS gene; colorectal cancer; field defect; hyperplastic polyp; methylation; microsatellite instability; sessile polyp

Year:  2017        PMID: 28694923      PMCID: PMC5498877     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  30 in total

1.  Microsatellite instability and the clinicopathological features of sporadic colorectal cancer.

Authors:  R Ward; A Meagher; I Tomlinson; T O'Connor; M Norrie; R Wu; N Hawkins
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

Review 2.  Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide.

Authors:  Lawrence J Burgart
Journal:  Arch Pathol Lab Med       Date:  2005-11       Impact factor: 5.534

3.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas.

Authors:  J M Cunningham; C Y Kim; E R Christensen; D J Tester; Y Parc; L J Burgart; K C Halling; S K McDonnell; D J Schaid; C Walsh Vockley; V Kubly; H Nelson; V V Michels; S N Thibodeau
Journal:  Am J Hum Genet       Date:  2001-08-24       Impact factor: 11.025

4.  Serrated lesions of the colorectum: review and recommendations from an expert panel.

Authors:  Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church
Journal:  Am J Gastroenterol       Date:  2012-06-19       Impact factor: 10.864

5.  Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer.

Authors:  Luigi Ricciardiello; Ajay Goel; Vilma Mantovani; Tania Fiorini; Stefania Fossi; Dong K Chang; Veronica Lunedei; Paolo Pozzato; Rocco M Zagari; Luca De Luca; Lorenzo Fuccio; Giuseppe N Martinelli; Enrico Roda; C Richard Boland; Franco Bazzoli
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

6.  Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening.

Authors:  Jenny N Poynter; Kimberly D Siegmund; Daniel J Weisenberger; Tiffany I Long; Stephen N Thibodeau; Noralane Lindor; Joanne Young; Mark A Jenkins; John L Hopper; John A Baron; Dan Buchanan; Graham Casey; A Joan Levine; Loïc Le Marchand; Steven Gallinger; Bharati Bapat; John D Potter; Polly A Newcomb; Robert W Haile; Peter W Laird
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 7.  Epigenetics of colorectal cancer.

Authors:  Ajay Goel; C Richard Boland
Journal:  Gastroenterology       Date:  2012-09-20       Impact factor: 22.682

8.  Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.

Authors:  W M Grady; R K Parkin; P S Mitchell; J H Lee; Y-H Kim; K D Tsuchiya; M K Washington; C Paraskeva; J K V Willson; A M Kaz; E M Kroh; A Allen; B R Fritz; S D Markowitz; M Tewari
Journal:  Oncogene       Date:  2008-02-11       Impact factor: 9.867

9.  A Big Bang model of human colorectal tumor growth.

Authors:  Andrea Sottoriva; Haeyoun Kang; Zhicheng Ma; Trevor A Graham; Matthew P Salomon; Junsong Zhao; Paul Marjoram; Kimberly Siegmund; Michael F Press; Darryl Shibata; Christina Curtis
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

10.  Colorectal adenomas contain multiple somatic mutations that do not coincide with synchronous adenocarcinoma specimens.

Authors:  José P Vaqué; Nerea Martínez; Ignacio Varela; Fidel Fernández; Marta Mayorga; Sophia Derdak; Sergi Beltrán; Thaidy Moreno; Carmen Almaraz; Gonzalo De Las Heras; Mónica Bayés; Ivo Gut; Javier Crespo; Miguel A Piris
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

View more
  1 in total

1.  Cancer-Associated Mutations in Normal Colorectal Mucosa Adjacent to Sporadic Neoplasia.

Authors:  Tianzuo Zhan; Sebastian Belle; Erica Valentini; Simon Herrmann; Thilo Miersch; Moying Li; Timo Gaiser; Michael Boutros; Matthias P Ebert; Johannes Betge
Journal:  Clin Transl Gastroenterol       Date:  2020-07       Impact factor: 4.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.